重组人干扰素α1b注射液联合阿糖腺苷对手足口病患儿免疫功能的影响

Effects of Recombinant Human Interferonα1b Injection Combined with Arabinoside on Children with Hfmd and Its Influence on Immune Function

目的探讨重组人干扰素α1b注射液联合阿糖腺苷对手足口病患儿免疫功能的影响。方法选取2018年7月至2020年7月沈阳市第六人民医院感染科收治的94例小儿手足口病患儿作为研究对象,随机分为试验组与对照组,各47例。对照组给予重组人干扰素α1b肌内注射治疗,试验组在对照组基础上联合单磷酸阿糖腺苷治疗。比较两组临床疗效、免疫球蛋白G(IgG)、免疫球蛋白M(IgM)、磷酸肌酸激酶同工酶(CK-MB)、乳酸脱氢同工酶(LDH-1)、白细胞介素-4(IL-4)、白细胞介素-6(IL-6)、白细胞介素-10(IL-10)水平、症状消退时间以及不良反应发生情况。结果与对照组比较,试验组治疗有效率较高,治疗后试验组IgM、IgG水平较高,CK-MB、LDH-1水平较低,差异有统计学意义(P<0.05);与对照组比较,治疗后试验组IL-4、IL-6、IL-10水平较低(P<0.05);与对照组比较,试验组皮疹消退时间、口腔疱疹消退时间、退热时间较短(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论重组人干扰素α1b注射液联合阿糖腺苷治疗小儿手足口病能够明显缩短康复时间,提高临床疗效,同时可减轻患儿心肌损伤,改善免疫功能。

Objective To investigate the effects of recombinant human interferonα1 b injection combined with arabinoside adenosine on children with hand foot mouth disease(HFMD).Methods A total of 94 children with HFMD admitted to the Department of Infectious Disease of Shenyang Sixth People’s Hospital were selected as the research objects and were randomly divided into a control group and a treatment group,with 47 cases in each group.The control group was given intramuscular injection of recombinant human interferonα1 b,and the test group was treated with arabinosine monophosphate plus intramuscular injection of recombinant human interferonα1 b.The clinical efficacy of the 2 groups,immunoglobulin G(IgG),immunoglobulin M(IgM),creatine kinase isoenzyme(CK-MB),lactate dehydrogenase(LDH-1),interleukin-4(IL-4),interleukin-6(IL-6),interleukin-10(IL-10)levels,time to resolution of symptoms,and occurrence of adverse reactions were compared between the 2 groups.Results Compared with the control group,the test group had a higher effective rate of treatment.After treatment,the test group had higher levels of IgM and IgG,and lower levels of CK-MB and LDH-1.The difference is statistically significant(P<0.05);compared with the control group,after treatment,the levels of IL-4,IL-6,and IL-10 in the test group were lower(P<0.05);compared with the control group,the time of rash remission,oral herpes remission,and fever in the test group were shorter(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the 2 groups(P>0.05).Conclusion Recombinant human interferonα1 b injection combined with arabinosine can significantly shorten the recovery time and improve the clinical efficacy of children with HMFD.At the same time,it can reduce the children’s myocardial injury and improve the immune function.